Equities analysts forecast that Zynerba Pharmaceuticals (NASDAQ:ZYNE) will announce earnings of ($0.74) per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Zynerba Pharmaceuticals’ earnings, with estimates ranging from ($0.84) to ($0.66). Zynerba Pharmaceuticals reported earnings of ($0.64) per share in the same quarter last year, which would suggest a negative year-over-year growth rate of 15.6%. The firm is expected to report its next quarterly earnings report on Tuesday, August 7th.
On average, analysts expect that Zynerba Pharmaceuticals will report full-year earnings of ($2.93) per share for the current financial year, with EPS estimates ranging from ($3.38) to ($2.57). For the next fiscal year, analysts anticipate that the company will post earnings of ($2.66) per share, with EPS estimates ranging from ($3.12) to ($2.36). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side research firms that that provide coverage for Zynerba Pharmaceuticals.
Zynerba Pharmaceuticals (NASDAQ:ZYNE) last posted its quarterly earnings data on Tuesday, May 8th. The company reported ($0.91) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.68) by ($0.23).
Several research firms have weighed in on ZYNE. HC Wainwright reaffirmed a “buy” rating and set a $23.00 price objective on shares of Zynerba Pharmaceuticals in a research report on Thursday, February 1st. Ladenburg Thalmann assumed coverage on shares of Zynerba Pharmaceuticals in a report on Monday, January 29th. They set a “buy” rating and a $25.50 target price for the company. Seaport Global Securities assumed coverage on shares of Zynerba Pharmaceuticals in a report on Friday, January 26th. They set a “buy” rating and a $16.00 target price for the company. Cantor Fitzgerald assumed coverage on shares of Zynerba Pharmaceuticals in a report on Monday, March 5th. They set a “buy” rating and a $17.00 target price for the company. Finally, ValuEngine upgraded shares of Zynerba Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, May 2nd. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and eight have issued a buy rating to the company’s stock. Zynerba Pharmaceuticals has a consensus rating of “Buy” and an average target price of $17.86.
In other Zynerba Pharmaceuticals news, major shareholder Michael Rapp bought 15,000 shares of the stock in a transaction dated Wednesday, May 2nd. The stock was purchased at an average cost of $10.46 per share, for a total transaction of $156,900.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 12.67% of the stock is currently owned by company insiders.
Hedge funds and other institutional investors have recently made changes to their positions in the stock. JPMorgan Chase & Co. raised its holdings in Zynerba Pharmaceuticals by 385.6% in the 1st quarter. JPMorgan Chase & Co. now owns 12,217 shares of the company’s stock worth $106,000 after acquiring an additional 9,701 shares during the last quarter. Alliancebernstein L.P. purchased a new position in Zynerba Pharmaceuticals in the 4th quarter worth approximately $264,000. Wells Fargo & Company MN raised its holdings in Zynerba Pharmaceuticals by 3,759.5% in the 3rd quarter. Wells Fargo & Company MN now owns 34,079 shares of the company’s stock worth $285,000 after acquiring an additional 33,196 shares during the last quarter. Alps Advisors Inc. raised its holdings in Zynerba Pharmaceuticals by 142.1% in the 1st quarter. Alps Advisors Inc. now owns 36,356 shares of the company’s stock worth $316,000 after acquiring an additional 21,337 shares during the last quarter. Finally, A.R.T. Advisors LLC raised its holdings in Zynerba Pharmaceuticals by 33.7% in the 1st quarter. A.R.T. Advisors LLC now owns 86,877 shares of the company’s stock worth $754,000 after acquiring an additional 21,879 shares during the last quarter. Institutional investors own 28.94% of the company’s stock.
Zynerba Pharmaceuticals traded up $0.47, hitting $10.28, during trading hours on Monday, MarketBeat reports. 286,248 shares of the stock traded hands, compared to its average volume of 222,113. The stock has a market cap of $133.04 million, a price-to-earnings ratio of -4.15 and a beta of 4.87. Zynerba Pharmaceuticals has a one year low of $5.42 and a one year high of $20.73.
Zynerba Pharmaceuticals Company Profile
Zynerba Pharmaceuticals, Inc operates as a clinical stage specialty pharmaceutical company. The company focuses on developing and commercializing pharmaceutically-produced transdermal cannabinoid treatments for rare or near-rare neuropsychiatric disorders. Its product candidates include ZYN002, which completed Phase II clinical trial for pediatric and adolescent patients with fragile X syndrome, pediatric and adolescent patients with developmental and epileptic encephalopathies, and adult patients with refractory epileptic focal seizures; and ZYN001 that is in Phase I clinical trial to treat Tourette syndrome.
Get a free copy of the Zacks research report on Zynerba Pharmaceuticals (ZYNE)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Zynerba Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zynerba Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.